Latest news with #2014
Yahoo
a day ago
- Sport
- Yahoo
Stephen A. Smith Is Still Not Happy With ESPN Suspension
Stephen A. Smith Is Still Not Happy With ESPN Suspension originally appeared on The Spun. ESPN's Stephen A. Smith is pretty much untouchable at this stage in his career. That wasn't always the case though. In 2014, Smith made a questionable remark about Ray Rice getting suspended for domestic violence. He told a national audience that he has implored the female members of his family to avoid provoking wrong actions. "I don't know how many times I got to reiterate that. But as a man who was raised by women, see, I know what I'm going to do if somebody touches a female member of my family. I know what I'm going to do, I know what my boys are going to do. I know what, I'm going to have to remind myself that I work for the Worldwide Leader, I'm going to have to get law enforcement officials involved because of what I'm going to be tempted to do," Smith said in July 2014. "But what I've tried to implore the female members of my family, some of who you all met and talked to and what have you, is that again, and this is what, I've done this all my life, let's make sure we don't do anything to provoke wrong actions. Because if I come, or somebody else come, whether it's law enforcement officials, your brother or the fellas that you know, if we come after somebody has put their hands on you, it doesn't negate the fact that they already put their hands on you. So, let's try to make sure that we can do our part in making sure that that doesn't happen." ESPN ultimately suspended Smith for a week because of his remarks about Rice and domestic violence. To this day, he disagrees with the network's decision. During an interview with Rolling Stone, the face of "First Take" said he didn't deserve a suspension for his comments. "Everybody and their mother advises me, 'Don't revisit it. It's a no-win situation.' To me, that's cowardice," Smith said, via Awful Announcing. "I know what I said. And what I did was utter the word 'provoke.' A former colleague at ESPN took it, ran with it, and it went ballistic on Twitter. The leadership at ESPN reacted to that. When the heat elevated, [they] said, 'We have to suspend you.' And that's a blemish on my career I do not believe I deserve. I've been consistent in that position. I'm a father of two daughters. I know what I've never condoned or excused. Unfortunately, we live in an immature society where people are not deducing right from wrong and contextualizing things properly." Even though his rant may have been a bit bizarre, Smith wasn't trying to excuse domestic violence. That being said, ESPN did what it felt was A. Smith Is Still Not Happy With ESPN Suspension first appeared on The Spun on Jun 19, 2025 This story was originally reported by The Spun on Jun 19, 2025, where it first appeared.
Yahoo
3 days ago
- Business
- Yahoo
QUADIENT SA: Availability of the share buyback program description
Paris, June 17, 2025 Quadient (Euronext Paris: QDT) announces the availability of the description of its share buyback program, launched by the Board of Directors on June 13, 2025, following the authorization granted by the Ordinary General Meeting held on June 13, 2025 (17th resolution). This description has been prepared in compliance with the provisions of Articles 241-1 et seq. of the General Regulation of the Autorité des Marchés Financiers (AMF), Articles L. 22-10-62 et seq. of the French Commercial Code, as well as the provisions of European Regulation No. 596/2014 and Delegated Regulation No. 2016/1052. This document can be consulted on the Company's investor relations website ( For more information, please contact: Anne-Sophie Jugean, Quadient+33 (0)1 45 36 30 Or visit our website: Attachment PDF
Yahoo
3 days ago
- Business
- Yahoo
QUADIENT SA: Availability of the share buyback program description
Paris, June 17, 2025 Quadient (Euronext Paris: QDT) announces the availability of the description of its share buyback program, launched by the Board of Directors on June 13, 2025, following the authorization granted by the Ordinary General Meeting held on June 13, 2025 (17th resolution). This description has been prepared in compliance with the provisions of Articles 241-1 et seq. of the General Regulation of the Autorité des Marchés Financiers (AMF), Articles L. 22-10-62 et seq. of the French Commercial Code, as well as the provisions of European Regulation No. 596/2014 and Delegated Regulation No. 2016/1052. This document can be consulted on the Company's investor relations website ( For more information, please contact: Anne-Sophie Jugean, Quadient+33 (0)1 45 36 30 Or visit our website: Attachment PDFError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company's managerial employees and their closely associated persons. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines®. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit and follow us on LinkedIn and Marisol Peron, Senior Vice President, Global Communications & Corporate AffairsT: +1 609 524 0065; E: mmp@ Andrew Carlsen, Vice President, Head of Investor RelationsT: +45 3377 9558; E: acn@ This Company Announcement contains forward looking statements. The words 'believe,' 'expect,' 'anticipate,' 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. Company Announcement no. 34CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A/SCarl Jacobsens Vej 302500 Valby Denmark Attachment 170625_CA34_Managerial Employee Transactions_FINALSign in to access your portfolio
Business Wire
3 days ago
- Business
- Business Wire
Arkema : Disclosure of Trading in Own Shares from 09 June to 13 June 2025
LA DÉFENSE, France--(BUSINESS WIRE)--Regulatory News: In accordance with applicable regulations, Arkema (Paris:AKE) announces having carried out the following share buyback transactions in accordance with Article 5 §2 of Regulation (EU) No 596/2014 from 09 June to 13 June 2025 Detailed information can be found on the Group Arkema website:
